Национальный Медицинский Университет Им. А.А. Богомольца
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Национальный Медицинский Университет Им. А.А. БогомольцаfiledCriticalНациональный Медицинский Университет Им. А.А. Богомольца
Priority to UAU201301169UpriorityCriticalpatent/UA80978U/en
Publication of UA80978UpublicationCriticalpatent/UA80978U/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
A method for treating non-alcoholic fatty liver disease in the patients with diabetes mellitus type 2 provides for the use of medicamentous agents. Prior to the beginning of the treatment, the functional state of the liver is assessed. The levels of total cholesterol and triglycerides are measured. Symbiter acidophilic concentrated is used as probiotic, one sachet () once a day with the meal or after the meal for 30 days.
UAU201301169U2013-01-312013-01-31Method for treating non-alcoholic fatty liver disease in patients with diabetes mellitus type 2
UA80978U
(en)
composition, dosage form, and methods for reducing the risk for mortality in an individual, the risk for a disease or condition in an individual, triglycerides in an individual's blood, an individual's resting heart rate, lipoprotein cholesterol non-high density in an individual, total cholesterol in an individual, apolipoprotein b in an individual blood, systolic blood pressure in an individual, and diastolic blood pressure in an individual, to prolong an individual's life, to treat hypertriglyceridemia in an individual and to increase an omega-3 index in an individual's red blood cells.
Pharmaceutical composition, use of 2-iminopyrrolidine derivative for production of pharmaceutical composition, and kit for treatment or amelioration of heart diseases.
Method for treatment of acute coronary syndrome without st-segment elevation in patients with ischemic heart disease and metabolic syndrome following percutaneous transluminar coronary angioplasty